CRM
Salesforce, Inc.
CRM offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
MRVL
Marvell Technology, Inc.
MRVL has a slight edge over CRM overall, supported by stronger modeled upside and stronger fundamentals.
CRM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
CRM's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
MRVL Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Healthy |
MRVL's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 20x | $218 | — |
| Cheap | 36x | $393 | +80% |
| Fair | 70x | $766 | +252% |
| Expensive | 293x | $3,206 | +1374% |
Historical ranges are pointers, not guarantees.
CRM has the edge over MRVL in the historical PE scenario, which offers more potential upside but is not a forecast.
MRVL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $51.02 | -69% |
| Fair | 25x | $75.19 | -54% |
| Forward | 25x | $164 | — |
| Current | 54x | $164 | — |
| Expensive | 71x | $215 | +31% |
Historical ranges are pointers, not guarantees.
MRVL's PE is in its expensive range at 54x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its fair range.
CRM Forward outlook
There aren't enough analyst estimates for CRM to show an outlook.
MRVL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for MRVL, with profitability improving.
CRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $10.96 | +59% |
| Q2 2026 | $8.63 | +35% |
| Q1 2026 | $7.80 | +23% |
| Q4 2025 | $7.49 | +23% |
| Q3 2025 | $6.88 | +20% |
| Q2 2025 | $6.39 | +15% |
| Q1 2025 | $6.36 | +51% |
| Q4 2024 | $6.08 | +131% |
CRM has the edge over MRVL on earnings, with more consistent year-over-year improvement.
MRVL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.51 | +116% |
| Q3 2026 | $3.02 | +$3.15 |
| Q2 2026 | $2.91 | +$3.48 |
| Q1 2026 | $3.07 | +$4.09 |
| Q4 2025 | $2.85 | +$4.55 |
| Q3 2025 | -$0.13 | +$0.98 |
| Q2 2025 | -$0.57 | +$0.56 |
| Q1 2025 | -$1.02 | +$0.06 |
| Q4 2024 | -$1.70 | -$1.05 |
MRVL has returned to profit: it earned $3.02 per share over the past year, after losing money the year before.
CRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3B | +11% |
| Q2 2026 | $11.1B | +13% |
| Q1 2026 | $11.2B | +12% |
| Q4 2025 | $10.3B | +8.6% |
| Q3 2025 | $10.2B | +9.8% |
| Q2 2025 | $9.8B | +7.6% |
| Q1 2025 | $10B | +7.6% |
| Q4 2024 | $9.4B | +8.3% |
CRM's revenue has grown year over year every quarter since late 2020: $11.3B last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -2.2 points |
| Q2 2026 | 21% | +1.3 points |
| Q1 2026 | 17% | -1.5 points |
| Q4 2025 | 21% | +1.3 points |
| Q3 2025 | 23% | +3.7 points |
| Q2 2025 | 20% | +1.1 points |
| Q1 2025 | 18% | +0.7 points |
| Q4 2024 | 20% | +2.8 points |
CRM has the edge over MRVL on profitability, with a higher operating margin.
MRVL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.7B | +37% |
| Q2 2026 | $2.4B | +28% |
| Q1 2026 | $2.2B | +22% |
| Q4 2025 | $2.1B | +37% |
| Q3 2025 | $2B | +58% |
| Q2 2025 | $1.9B | +63% |
| Q1 2025 | $1.8B | +27% |
| Q4 2024 | $1.5B | +6.9% |
MRVL has the edge over CRM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +2.3 points |
| Q2 2026 | 14% | -0.2 points |
| Q1 2026 | 18% | +5.3 points |
| Q4 2025 | 17% | +64 points |
| Q3 2025 | 14% | +22 points |
| Q2 2025 | 14% | +27 points |
| Q1 2025 | 13% | +15 points |
| Q4 2024 | -46% | -36 points |
MRVL's operating margin was 17% last quarter, up 2.3 points from the same quarter a year ago.
CRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +81% |
| Q2 2026 | $6.6B | +4.1% |
| Q1 2026 | $5.3B | +39% |
| Q4 2025 | $2.2B | +22% |
| Q3 2025 | $605M | -20% |
| Q2 2025 | $6.3B | +3.5% |
| Q1 2025 | $3.8B | +17% |
| Q4 2024 | $1.8B | +30% |
CRM has the edge over MRVL on cash flow, with more consistent year-over-year improvement.
MRVL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $478.8M | +16% |
| Q2 2026 | $483.1M | +126% |
| Q1 2026 | $259.4M | -42% |
| Q4 2025 | $508.8M | +10% |
| Q3 2025 | $414.1M | +60% |
| Q2 2025 | $214.1M | -8.1% |
| Q1 2025 | $444.1M | -6.6% |
| Q4 2024 | $461.3M | +2.8% |
MRVL generated $1.7B in free cash flow over the past year, up 13% from the year before.
CRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.7% | -50M shares |
| 1 year | -15% | -141M shares |
| 3 years | -17% | -165M shares |
| 5 years | -14% | -129M shares |
| Available history | -6.6% | -58M shares |
CRM has the edge over MRVL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $84M |
| Q2 2026 | $27.2B |
| Q1 2026 | $3.9B |
| Q4 2025 | $3.8B |
| Q3 2025 | $2.2B |
| Q2 2025 | $2.6B |
| Q1 2025 | $76M |
| Q4 2024 | $1.3B |
CRM spent $35.1B buying back its own shares over the past year, about six times what it spent the year before.
MRVL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +27.9M shares |
| 1 year | +5.8% | +50.8M shares |
| 3 years | +7% | +60.3M shares |
| 5 years | +12% | +100M shares |
| Available history | +38% | +253M shares |
MRVL has 921M diluted shares, up 5.8% from a year ago, despite $1.9B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $200M |
| Q2 2026 | $200M |
| Q1 2026 | $200.1M |
| Q4 2025 | $1.3B |
| Q3 2025 | $200M |
| Q2 2025 | $340M |
| Q1 2025 | $200M |
| Q4 2024 | $200M |
MRVL spent $1.9B buying back its own shares over the past year, up 102% from the year before.
CRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | 0.0x | Very low |
CRM's net debt is about 2.5 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
MRVL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 1.5x | Healthy |
| Q4 2020 | 0.5x | Very low |
| Q3 2020 | 0.6x | Very low |
| Q2 2020 | 0.7x | Very low |
| Q1 2020 | 0.7x | Very low |
| Q4 2019 | 5.3x | High |
MRVL's net debt is about 1.5 years of its operating earnings (EBITDA), up from less than a year a year ago.
CRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 44.2 | Neutral |
CRM's weekly RSI is 51 (neutral) and its Stochastic is 44 (neutral).
MRVL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 16.1 | Oversold |
MRVL's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
CRM PE vs Technology Sector
| Metric | CRM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 29% below |
| PE % | 2 | 35 | 33 pts below |
CRM has the edge over MRVL on valuation relative to its sector.
MRVL PE vs Technology Sector
| Metric | MRVL | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 28x | 95% above |
| PE % | 75 | 35 | 40 pts above |
MRVL is trading at 54x earnings, a 95% premium to the Technology sector's median of 28x.
CRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $230.9 | 5.8% below |
| 20 week MA | $214.7 | 1.3% above |
| 50 week MA | $206.8 | 5.2% above |
| 100 week MA | $239.7 | 9.2% below |
| 200 week MA | $242.0 | 10% below |
CRM's trend is mixed: it's above two of its five weekly moving averages, and 10% below its 200-week average.
MRVL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $221.0 | 26% below |
| 20 week MA | $220.9 | 26% below |
| 50 week MA | $168.8 | 2.5% below |
| 100 week MA | $124.8 | 32% above |
| 200 week MA | $93.8 | 75% above |
MRVL has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 75% above its 200-week average.
CRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $165.0 | $225.8 | +37% |
| 2021 | $225.8 | $253.1 | +12% |
| 2022 | $253.1 | $129.4 | -49% |
| 2023 | $129.4 | $263.1 | +103% |
| 2024 | $263.1 | $338.5 | +29% |
| 2025 | $338.5 | $266.1 | -21% |
| 2026 YTD | $266.1 | $217.6 | -18% |
CRM's yearly returns have swung widely, from +103% in 2023 to −49% in 2022. It's down 18% so far in 2026.
MRVL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.7 | $47.1 | +76% |
| 2021 | $47.1 | $87.7 | +86% |
| 2022 | $87.7 | $37.2 | -58% |
| 2023 | $37.2 | $60.3 | +62% |
| 2024 | $60.3 | $113.6 | +88% |
| 2025 | $113.6 | $86.3 | -24% |
| 2026 YTD | $86.3 | $164.5 | +90% |
MRVL has the edge over CRM on returns for 2026, with the stronger performance.